Neovasc announces German reimbursement renewal

Neovasc announced the German Institute for the Hospital Remuneration System has awarded the Neovasc Reducer, a CE-Marked medical device for the treatment of refractory angina, NUB Status 1 designation for 2023. New examination and treatment methods are comprised of novel and innovative medicines, medical products and procedures that can be utilized by hospitals before reaching full reimbursement eligibility. The NUB process opens the path for negotiations between hospitals and health insurers for the reimbursement of new medical treatments in the German healthcare system. InEK is responsible for prioritizing new therapies in Germany through the NUB process. Reducer has been granted Status 1, the highest priority designation available. The NUB decision is valid for one year and can be renewed annually. For 2023, 329 German hospitals applied for the Reducer NUB, up from 256 in 2022, and they can now negotiate full reimbursement coverage for the Reducer therapy.